Elos Medtech Valuation

Is ELOS B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ELOS B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ELOS B (SEK203) is trading above our estimate of fair value (SEK21.73)

Significantly Below Fair Value: ELOS B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ELOS B?

Key metric: As ELOS B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ELOS B. This is calculated by dividing ELOS B's market cap by their current earnings.
What is ELOS B's PE Ratio?
PE Ratio	104.3x
Earnings	SEK 54.95m
Market Cap	SEK 5.73b

ELOS B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.9x
Enterprise Value/EBITDA	30.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ELOS B's PE Ratio compare to its peers?

The above table shows the PE ratio for ELOS B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	31.7x
SUS Surgical Science Sweden	38.6x	36.1%	SEK 7.5b
CEVI CellaVision	34.1x	22.8%	SEK 5.1b
ARJO B Arjo	17.7x	24.5%	SEK 8.9b
STIL Stille	36.6x	36.8%	SEK 1.9b
ELOS B Elos Medtech	104.3x	n/a	SEK 5.7b

Price-To-Earnings vs Peers: ELOS B is expensive based on its Price-To-Earnings Ratio (104.3x) compared to the peer average (41.9x).

Price to Earnings Ratio vs Industry

How does ELOS B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ELOS B is expensive based on its Price-To-Earnings Ratio (104.3x) compared to the European Medical Equipment industry average (31.3x).

Price to Earnings Ratio vs Fair Ratio

What is ELOS B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ELOS B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	104.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ELOS B's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 144.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.95

1.4%

47.0%

Dignitana

SEK 96.7m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.20

4.3%

-45.5%

Iconovo

SEK 79.9m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.02

-1.6%

-46.3%